OPEN ACCESS Freely available online

Journal of Clinical Toxicology

Commentary

Excitotoxicity and the Glutamate Cascade in Brain Disorders

Svetlana P. Ivanova*

Institute of Molecular and Environmental Toxicology, North Volga Research University, Velograd, Volgograd Oblast, Russia

DESCRIPTION

Excitotoxicity is a pathological process by which nerve cells are damaged and killed due to excessive stimulation by neurotransmitters such as glutamate. This phenomenon, first described in the late 1960s, has since been recognized as a pivotal mechanism in a range of neurological disorders including stroke, traumatic brain injury, epilepsy and neurodegenerative diseases like Alzheimer's disease, Parkinson's disease and Amyotrophic Lateral Sclerosis (ALS) [1,2].

At the cellular level, excitotoxicity primarily involves the overactivation of ionotropic glutamate receptors, particularly the N-methyl-D-aspartate (NMDA) and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors. When these receptors are overstimulated, there is a massive influx of calcium ions into the neuron. While calcium is vital for normal cellular function, its excessive intracellular accumulation triggers a cascade of deleterious events. These include activation of calcium-dependent enzymes such as proteases, lipases, and endonucleases, leading to breakdown of cellular structures, mitochondrial dysfunction, generation of Reactive Oxygen Species (ROS) and ultimately, neuronal death [3].

The role of mitochondria in excitotoxicity is particularly critical. Mitochondria buffer intracellular calcium, but during excitotoxic events, their capacity is overwhelmed. This leads to mitochondrial swelling, release of pro-apoptotic factors such as cytochrome c and increased ROS production, further amplifying neuronal injury. Furthermore, the dysfunction of energy metabolism due to impaired mitochondrial function exacerbates the vulnerability of neurons, especially in metabolically demanding regions such as the hippocampus and cortex [4].

In the context of acute events such as ischemic stroke, excitotoxicity unfolds rapidly. The sudden deprivation of oxygen and glucose leads to failure of ATP-dependent ion pumps, causing membrane depolarization and uncontrolled release of glutamate into the synaptic cleft. The absence of proper reuptake by glial cells further increases glutamate levels, intensifying excitotoxic damage. This has led to intensive research into glutamate receptor antagonists as potential therapeutic agents. Although promising in preclinical models, most NMDA receptor antagonists have failed in clinical trials due to severe side effects or lack of efficacy, possibly due to the narrow therapeutic time window and the diverse roles of NMDA receptors in normal brain function [5].

Excitotoxicity also plays a subtler, chronic role in neurodegenerative diseases. In Alzheimer's disease, for example, amyloid-β oligomers have been shown to enhance NMDA receptor activity and disrupt glutamate transport, thus promoting excitotoxic signaling. Similarly, in ALS, mutations in glutamate transporters like EAAT2 (excitatory amino acid transporter 2) impair glutamate clearance, facilitating excitotoxic damage to motor neurons [6].

Emerging research is now focusing on more targeted strategies to mitigate excitotoxicity. These include modulation of specific NMDA receptor subtypes, enhancement of glutamate uptake by astrocytes, and stabilization of mitochondrial function. Novel approaches such as RNA interference, gene therapy and antioxidant therapies are also being explored to suppress excitotoxic cascades without interfering with the physiological roles of glutamate.

In conclusion, excitotoxicity remains a central concept in the pathophysiology of numerous neurological disorders. While challenges persist in translating experimental insights into clinical therapies, continued research on the molecular underpinnings and modulation of excitotoxic pathways holds promise for the development of more effective neuroprotective strategies.

REFERENCES

1. Olney JW. Brain lesions, obesity, and other disturbances in mice treated with monosodium glutamate. Science. 1969;164:719–721.
2. Dong XX, Wang Y, Qin ZH. Molecular mechanisms of excitotoxicity and their relevance to pathogenesis of neurodegenerative diseases. Acta Pharmacol Sin. 2009;30:379–387.
3. Nicholls DG. Mitochondrial dysfunction and glutamate excitotoxicity studied in primary neuronal cultures. Curr Mol Med. 2004;4:149–177.

Correspondence to: Institute of Molecular and Environmental Toxicology, North Volga Research University, Velograd, Volgograd Oblast, Russia, E-mail: s.ivanova@nvru.ac.ru

Received: 04-Mar-2025, Manuscript No. JCT-25-37524; **Editor assigned:** 06-Mar-2025, PreQC No. JCT-25-37524 (PQ); **Reviewed:** 20-Mar-2025, QC No. JCT-25-37524; **Revised:** 26-Mar-2025, Manuscript No. JCT-25-37524 (R); **Published:** 01-Apr-2025, DOI: 10.35248/2475-3181.25.15.589

Citation: Ivanova SP (2025). Excitotoxicity and the Glutamate Cascade in Brain Disorders. J Clin Toxicol. 15:589.

4. Wang R, Reddy PH. Role of Glutamate and NMDA Receptors in Alzheimer's Disease. J Alzheimers Dis. 2017;57:1041–1048.
5. Lipton SA. Paradigm shift in neuroprotection by NMDA receptor blockade: Memantine and beyond. Nat Rev Drug Discov. 2006;5:160–170.
6. Rao SD, Weiss JH. Excitotoxic and oxidative cross-talk in neuronal death. Trends Neurosci. 2004;27:496–503.